Compare Lowe`s Companies Inc (LOW) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Natera Inc. Common Stock — how do they compare? Lowe`s Companies Inc trades at $189.78 (market cap $105.89B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Lowe`s Companies Inc is the larger of the two by market cap, and Lowe`s Companies Inc pays a 2.65% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lowe`s Companies Inc for 98 Days and Natera Inc. Common Stock for 0 Days on average.
| LOW | NTRA | |
|---|---|---|
Market Cap | $105.89B | $57.03B |
Volume | 3,104,115 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $425.64 |
52-Week Low | $179.50 | $179.42 |
Typical Hold Time | 98 Days | 0 Days |
Enterprise Value | $144.74B | $56.18B |
Dividend Yield | 2.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $188.36, up 1.5% with recent earnings beats but facing industry headwinds. The stock shows bearish technical signals despite positive analyst sentiment with a $244.09 consensus target. Revenue declined to $83.67B in 2025, though net margins remain healthy at 7.35%. Recent drone delivery initiatives with DoorDash and Alphabet aim to enhance competitiveness amid a challenging home improvement market.
LOW presents a value opportunity with reasonable P/E (15.95) and strong cash flow, but risks include declining revenue trends, high debt levels, and housing market sensitivity. Wall Street maintains bullish ratings (61% buy) despite near-term pressure, suggesting potential upside if execution improves.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
